242 576

Cited 13 times in

Treatment Outcome of Transcatheter Arterial Chemoinfusion According to Anticancer Agents and Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma (TNM Stage IVa)

 Sang Hoon Ahn  ;  Kwang Hyub Han  ;  Jong Tae Lee  ;  Do Yun Lee  ;  Young Myoung Moon  ;  Chae Yoon Chon  ;  Kwan Sik Lee  ;  Chang Mo Moon  ;  Young Hoon Youn  ;  Jeong Youp Park 
 YONSEI MEDICAL JOURNAL, Vol.45(5) : 847-858, 2004 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Agents/administration & dosage* ; Antineoplastic Agents/adverse effects ; Carcinoma, Hepatocellular/drug therapy* ; Carcinoma, Hepatocellular/mortality ; Cause of Death ; Female ; Humans ; Infusions, Intra-Arterial* ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Prognosis ; Survival Rate ; alpha-Fetoproteins/analysis
Hepatocellular carcinoma ; transcatheter arterial chemoinfusion ; treatment outcome ; prognostic factors
Transcatheter arterial chemoinfusion (TACI) is the main treatment modality for advanced hepatocellular carcinoma (HCC). However, the therapeutic efficacy of TACI according to anti-cancer agents and prognostic factors for advanced HCC (TNM stage IVa) has not been previously clarified. A total of 127 patients with TNM stage IVa HCC were divided into intra-arterial Adriamycin (Group I) and intra-arterial Cisplatin (Group II) infused groups, according to the anticancer agents that were used. We compared the therapeutic efficacy of TACI applied anticancer agents, and we also analyzed the prognostic factors which influenced the survival rates. Chi-square test, t-test, Cox's proportional hazard regression model, and Kaplan-Meier method were performed. The overall survival was significantly different (10.0 vs 5.7 months, respectively) and the results favored Group I. On univariate analysis, the significant prognostic factors included age, portal vein thrombosis (PVT), tumor size (diameter > 5 cm), type of tumor, the reduction rate (tumor size & alpha-fetoprotein) after 3 months of chemotherapy, serum albumin level, serum alkaline phosphatase level and total serum bilirubin levels at the time of diagnosis. After repeated chemotherapy, Group I showed better survival (14.0 vs 7.9 months). However, there was no statistical difference in the survival rate of the two groups for cases involving large tumors, PVT and diffuse type of HCC. Group I showed better survival than Group II. However, when the other prognostic factors were taken into consideration, there was no significant difference in the survival rate of the two groups, except for the cases with small or nodular HCC.
Files in This Item:
T200401428.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Moon, Chang Mo(문창모)
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Youn, Young Hoon(윤영훈) ORCID logo https://orcid.org/0000-0002-0071-229X
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Lee, Do Yun(이도연)
Lee, Jong Tae(이종태)
Chon, Chae Yoon(전재윤)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.